Login / Signup

Barriers and Enablers Affecting the Uptake of Biosimilar Medicines Viewed Through the Lens of Actor Network Theory: A Systematic Review.

Chad RiegerJudith A DeanLisa HallPaola VasquezGregory Merlo
Published in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2024)
Barriers and enablers affecting uptake of biosimilars are interconnected within networks, and can be divided into systemic, HCP, and patient categories. Understanding the agency of actors within networks may allow for more comprehensive and effective approaches. Systemic enablers in the form of policies appear to be the most effective overall levers in affecting uptake of biosimilars, with policy makers advised to give careful consideration to appropriately educating HCPs and positively framing biosimilars for patients.
Keyphrases
  • end stage renal disease
  • public health
  • newly diagnosed
  • chronic kidney disease
  • ejection fraction
  • healthcare
  • prognostic factors
  • case report
  • peritoneal dialysis
  • patient reported outcomes
  • drug induced